(Rac)-Ruxolitinib-d9

• CAT Number: S000434
• CAS Number: 2469553-67-9
• Molecular Formula: C17H9D9N6
• Molecular Weight: 315.42
• Purity: ≥95%
• IUPAC Name: 3-(1,2,2,3,3,4,4,5,5-nonadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
• InChI: InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/i1D2,2D2,3D2,4D2,12D
• InChIKey: HFNKQEVNSGCOJV-WHCQKTAPSA-N
• SMILES: C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

(Rac)-Ruxolitinib-d9（Cat No.:S000434） is a deuterated version of ruxolitinib, where nine hydrogen atoms are replaced with deuterium. This alteration is particularly useful for pharmacokinetic and metabolic research, enhancing the drug’s stability and traceability in biological systems. Ruxolitinib, a medication used to treat myelofibrosis and polycythemia vera, functions by inhibiting Janus kinases (JAK1 and JAK2), which are critical for the signaling pathways that regulate blood and immune cell production. The deuterated form, (Rac)-Ruxolitinib-d9, allows researchers to study more precisely how the drug is metabolized and its interaction dynamics within the body.